Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

Thibault Mazard,Marc Ychou,Simon Thezenas,Sylvain Poujol,Frédéric Pinguet,Agnès Thirion,Jean-Pierre Bleuse,Fabienne Portales,Emmanuelle Samalin,Eric Assenat

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

2012

Thibault Mazard
Marc Ychou
Simon Thezenas
Sylvain Poujol
Frédéric Pinguet
Agnès Thirion
Jean-Pierre Bleuse
Fabienne Portales
Emmanuelle Samalin
Eric Assenat

Background Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.

Keywords:

Capecitabine
XELIRI
Cancer
Irinotecan
Oxaliplatin
Oncology
Capecitabine/irinotecan
Chemotherapy
Internal medicine
Medicine
combination chemotherapy
Fluorouracil
Camptothecin
Deoxycytidine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations